We are live on ! Find out more
Ken Griffin

Ken Griffin Citadel Advisors

AUM $618B
1-Year Est. Return 30.34%
 

Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.

This Fund
S&P 500
This Quarter Est. Return
+22.33%
1 Year Est. Return
+30.34%
3 Year Est. Return
+94.87%
5 Year Est. Return
+105.94%
10 Year Est. Return
+434.06%
AUM
$385B
AUM Growth
+$32.1B
Cap. Flow
-$35.1B
Cap. Flow %
-9.14%
Top 10 Hldgs %
30.5%
Holding
11,975
New
1,989
Increased
4,461
Reduced
4,218
Closed
1,130

Sector Composition

Rank Sector Weight
1 Technology 3.66%
2 Healthcare 3.16%
3 Industrials 2.01%
4 Financials 1.98%
5 Consumer Discretionary 1.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CALC icon
10801
CalciMedica
CALC
$19.1M
-27,878
Closed -$4.96M
CANF
10802
Can-Fite BioPharma American Depositary Shares
CANF
$7.28M
-59
Closed -$21K
CANG
10803
Cango Inc
CANG
$92.7M
-2,021
Closed -$112K
CARE icon
10804
Carter Bankshares
CARE
$749M
-16,786
Closed -$112K
CARM
10805
CALL
DELISTED
Carisma Therapeutics
CARM
-1,785
Closed -$50K
CATO icon
10806
PUT
Cato Corp
CATO
$65.7M
-21,600
Closed -$169K
CBU icon
10807
PUT
Community Bank
CBU
$3.43B
-7,000
Closed -$381K
CCAP icon
10808
Crescent Capital BDC
CCAP
$408M
-12,110
Closed -$154K
CDLX icon
10809
Cardlytics
CDLX
$24.7M
-1,940
Closed -$2.07M
CELG.RT
10810
Bristol-Myers Squibb Rights
CELG.RT
$187M
-20,251
Closed -$8K
CENN icon
10811
Cenntro
CENN
$8.53M
-115
Closed -$115K
CFFN icon
10812
CALL
Capitol Federal Financial
CFFN
$1.1B
-15,700
Closed -$145K
CG icon
10813
Carlyle Group
CG
$17.2B
-53,224
Closed -$1.5M
CFR icon
10814
Cullen/Frost Bankers
CFR
$10.4B
-23,523
Closed -$1.85M
CGC
10815
Canopy Growth
CGC
$426M
-35,088
Closed -$8M
MBAI
10816
Check-Cap
MBAI
$1.4M
-1,300
Closed -$66K
CHH icon
10817
CALL
Choice Hotels
CHH
$4.71B
-2,500
Closed -$215K
CHH icon
10818
PUT
Choice Hotels
CHH
$4.71B
-4,100
Closed -$352K
CHMI
10819
Cherry Hill Mortgage Investment Corp
CHMI
$107M
-61,432
Closed -$552K
CHRS icon
10820
CALL
Coherus Oncology
CHRS
$181M
-11,500
Closed -$211K
CI icon
10821
Cigna
CI
$73.5B
-272,462
Closed -$53.4M
CIEN icon
10822
Ciena
CIEN
$62.7B
-387,938
Closed -$17.2M
CIO
10823
CALL
DELISTED
City Office REIT
CIO
-15,700
Closed -$118K
CLBK icon
10824
Columbia Financial
CLBK
$1.21B
-55,746
Closed -$771K
CLVT icon
10825
Clarivate
CLVT
$1.25B
-127,548
Closed -$3.77M

Similar funds

Ken Griffin's Q4 2020 Portfolio in Review

As of Q4 2020, Ken Griffin held 11,975 positions worth $385B, up 9.1% from $353B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Ken Griffin withdrew a net $35.1B in Q4 2020, closing 1,130 positions and reducing 4,218 holdings. Its most notable exit was Immunomedics Inc, an estimated $213M position sold in full.

By sector, the portfolio is most concentrated in Technology at 3.7% of assets, up from 3% a quarter earlier, followed by Healthcare and Industrials.

Against the trend, Ken Griffin opened a new position in S&P Global worth $114M.

  • Ken Griffin's largest Q4 2020 buy was S&P Global: 345,785 shares worth $114M.
  • Ken Griffin added most to iShares Core S&P 500 ETF in Q4 2020, an estimated $1.16B increase.
  • Ken Griffin's biggest Q4 2020 reduction was Amazon, cutting an estimated $1.55B.
  • Ken Griffin fully exited Immunomedics Inc in Q4 2020, selling an estimated $213M.
  • Ken Griffin's ten largest holdings make up 31% of its $385B portfolio in Q4 2020.
  • Ken Griffin opened 1,989 new positions and closed 1,130 in Q4 2020.
  • Ken Griffin's portfolio value rose 9.1% quarter-over-quarter to $385B.

Based on Citadel Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.